文献速递头颈部肿瘤放疗

鼻咽癌调强放疗后听力损伤风险因素的评估与分析

Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy.
PubMed 文献 · Radiother Oncol · 2023-11-04

本研究基于588例2010至2016年在中山大学肿瘤防治中心接受调强放疗的非转移性鼻咽癌青少年及年轻成人患者,中位随访103.4个月,分析听力损伤(HI)与严重听力损伤(SHI)的概率并构建列线图进行个体化预测。HI发生率为39.5%,SHI为29.7%;HI的前兆因素为内耳45 Gy体积(IEV45)和听内道50 Gy体积(IACV50),SHI为IACmin和IACV60,列线图区分能力良好(c-index分别为0.806和0.793)。作者建议HI的剂量限制为IEV45<50%和/或IACV50<40%,SHI为IACmin<44 Gy和/或IACV60<40%。

要点

  • 588例鼻咽癌IMRT后中位随访103.4个月,HI发生率39.5%,SHI发生率29.7%。
  • HI前兆因素为IEV45和IACV50,SHI前兆因素为IACmin和IACV60。
  • 预测HI与SHI的列线图c-index分别为0.806和0.793。

核心结论

  • 综合分析可预测鼻咽癌IMRT后HI和SHI的风险,作者提出合理的剂量限制建议,以改善长期生活质量。

研究设计与样本

  • 单中心回顾性研究,纳入2010至2016年在中山大学肿瘤防治中心接受调强放疗的588例非转移性鼻咽癌青少年及年轻成人患者。
  • 采用LASSO logistic回归模型和单变量分析筛选潜在风险因素,以一致性指数和校准曲线评估列线图预测能力,并进行bootstrap重采样验证。

主要发现

  • 588例鼻咽癌患者中位随访103.4个月,HI发生于39.5%的患者,29.7%经历SHI。
  • HI的前兆因素为内耳45 Gy体积(IEV45)和听内道50 Gy体积(IACV50),SHI的前兆因素为IACmin和IACV60。
  • 预测HI和SHI概率的列线图区分能力良好,c-index分别为0.806和0.793。

关键数值与推荐

  • 作者建议HI的合理剂量限制为IEV45<50%和/或IACV50<40%。
  • 作者建议SHI的合理剂量限制为IACmin<44 Gy和/或IACV60<40%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treating nasopharyngeal carcinoma (NPC) with radiotherapy frequently causes hearing impairment (HI). HI risk data haven't been evaluated quantitatively. This study aimed to analyze the probability of HI and sever HI (SHI), develop a nomogram to quantify individual prediction, and provide dose limitation suggestions. METHODS AND MATERIALS: This single-center, retrospective study was conducted based on 588 adolescents and young adults with non-metastatic NPC treated using intensity modulated radiation therapy (IMRT) at Sun Yat-sen University Cancer Center between 2010 and 2016. A least absolute shrinkage and selection operator (LASSO) logistic regression model and univariate analysis were used to screen potential risk factors. The concordance index and a calibration curve evaluated the nomogram models' predictive ability, with bootstrap resampling validation. RESULTS: We analyzed 588 patients with NPC, with a median follow-up of 103.4 months. HI occurred in 39.5 % of patients, with 29.7 % experiencing SHI. Two factors were classified as precursors for HI (volume 45 Gy of the inner ear (IEV45) and volume 50 Gy of the internal auditory canal (IACV50)), and IACmin and IACV60 for SHI, respectively. Prognostic nomograms were developed to predict HI and SHI probabilities, showing excellent discriminative abilities (c-index values = 0.806 and 0.793, respectively). We also suggested IEV45 < 50 % and/or IACV50 < 40 % as rational dose limitations for HI, and IACmin < 44 Gy and/or the IACV60 < 40 % for SHI. CONCLUSION: Comprehensive analysis could predict the risk of HI and SHI in NPC after IMRT, proposing rational dose limitations and improving long-term quality of life.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chen L, Li J, Li K, et al. Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy. Radiother Oncol. 2023. PMID: 37926330. doi:10.1016/j.radonc.2023.109985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。